AMA asks FDA to hold cannabis botanicals to drug evidence standards

The American Medical Association urged FDA to require clinical evidence and postmarket safety oversight for cannabis and other botanical products while supporting a special research schedule for cannabis. Oklahoma operators should avoid unsupported therapeutic claims and track whether federal agencies create a distinct research pathway.